This inventor holds 1 USPTO granted patent. Top assignees: Dana-Farber-Cancer Institute Inc., Harvard College. Active years: 2026.
Company Filing History:
1 out of 1,264 
1 out of 3,069 
Years Active: 2026
Title: James Eaglesham: Innovator in Nucleotidyltransferases
Introduction
James Eaglesham is a notable inventor based in Boston, MA. He has made significant contributions to the field of biochemistry, particularly in the area of nucleotidyltransferases. His work has implications for various applications in molecular biology and medicine.
Latest Patents
James Eaglesham holds a patent for "CGAS/DNCV-like nucleotidyltransferases and uses thereof." This invention is based on the discovery and characterization of the CD-NTase family of proteins. It includes compositions comprising CD-NTases, methods of producing nucleotide-based second messengers using such polypeptides, and methods of screening for modulators of the structure, expression, and/or activity of these polypeptides. He has 1 patent to his name.
Career Highlights
Throughout his career, James has worked with prestigious institutions such as Harvard College and Dana-Farber Cancer Institute Inc. His research has contributed to advancements in understanding nucleotide signaling pathways.
Collaborations
James has collaborated with notable colleagues, including Philip J. Kranzusch and Aaron T. Whiteley. Their combined expertise has furthered research in the field of nucleotidyltransferases.
Conclusion
James Eaglesham's innovative work in nucleotidyltransferases showcases his dedication to advancing scientific knowledge. His contributions have the potential to impact various fields, including molecular biology and therapeutic development.